RxDoctor Payments Data

Alla Zhukova, MD

Family Medicine · Cape Coral, FLNPI 1194952788

Payments from drug & device makers

$763in general payments, 2019–2025

Across 55 payments — averaging $13.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$154
  • Novo Nordisk$146
  • Astellas Pharma US Inc$145
  • AstraZeneca$62
  • Sanofi-aventis U.S. LLC$52
  • Novartis$41
  • plus $162 from 6 others

What the payments were for

  • Food & beverage$763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$763 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$153,388
Medicare patients
409
Services billed
2,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$121,675
JardianceEmpagliflozin79$113,649
OzempicSemaglutide45$82,387
XareltoRivaroxaban44$65,361
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$56,066
RybelsusSemaglutide24$52,641
JanuviaSitagliptin Phosphate39$52,635
ProliaDenosumab26$44,167
Tresiba Flextouch U-100Insulin Degludec22$27,665
MounjaroTirzepatide18$27,020
Repatha SureclickEvolocumab16$25,743
Breo ElliptaFluticasone/Vilanterol28$25,517
MyrbetriqMirabegron16$24,268
FarxigaDapagliflozin Propanediol23$20,314
LinzessLinaclotide12$19,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$146$135,02969 claims
PfizerEliquis$26$121,675119 claims
GSKTrelegy Ellipta, Breo Ellipta$39$81,58370 claims
Johnson & JohnsonXarelto$154$65,36144 claims
MerckJanuvia$25$52,63539 claims
AmgenProlia$26$44,16726 claims
AstraZenecaFarxiga, Symbicort$62$25,28137 claims
Astellas Pharma US IncMyrbetriq$145$24,26816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →